Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis

T. Tran, M. Šterclová, N. Mogulkoc, K. Lewandowska, V. Müller, M. Hájková, MR. Kramer, D. Jovanović, J. Tekavec-Trkanjec, M. Studnicka, N. Stoeva, K. Hejduk, L. Dušek, S. Suissa, M. Vašáková, EMPIRE registry,

. 2020 ; 21 (1) : 11. [pub] 20200108

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028612

BACKGROUND: Several registries of idiopathic pulmonary fibrosis (IPF) have been established to better understand its natural history, though their size and duration of follow-up are limited. Here, we describe the large European MultiPartner IPF Registry (EMPIRE) and validate predictors of long-term survival in IPF. METHODS: The multinational prospective EMPIRE registry enrolled IPF patients from 48 sites in 10 Central and Eastern European countries since 2014. Survival from IPF diagnosis until death was estimated, accounting for left-truncation. The Cox proportional hazards regression model was used to estimate adjusted hazard ratios (HR) of death for prognostic factors, using restricted cubic splines to fit continuous factors. RESULTS: The cohort included 1620 patients (mean age at diagnosis 67.6 years, 71% male, 63% smoking history), including 75% enrolled within 6 months of diagnosis. Median survival was 4.5 years, with 45% surviving 5 years post-diagnosis. Compared with GAP stage I, mortality was higher with GAP stages II (HR 2.9; 95% CI: 2.3-3.7) and III (HR 4.0; 95% CI: 2.8-5.7) while, with redefined cut-offs, the corresponding HRs were 2.7 (95% CI: 1.8-4.0) and 5.8 (95% CI: 4.0-8.3) respectively. Mortality was higher with concurrent pulmonary hypertension (HR 2.0; 95% CI: 1.5-2.9) and lung cancer (HR 2.6; 95% CI: 1.3-4.9). CONCLUSIONS: EMPIRE, one of the largest long-term registries of patients with IPF, provides a more accurate confirmation of prognostic factors and co-morbidities on longer term five-year mortality. It also suggests that some fine-tuning of the indices for mortality may provide a more accurate long-term prognostic profile for these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028612
003      
CZ-PrNML
005      
20210114154439.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12931-019-1271-z $2 doi
035    __
$a (PubMed)31915023
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Tran, Tanja $u Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
245    14
$a The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis / $c T. Tran, M. Šterclová, N. Mogulkoc, K. Lewandowska, V. Müller, M. Hájková, MR. Kramer, D. Jovanović, J. Tekavec-Trkanjec, M. Studnicka, N. Stoeva, K. Hejduk, L. Dušek, S. Suissa, M. Vašáková, EMPIRE registry,
520    9_
$a BACKGROUND: Several registries of idiopathic pulmonary fibrosis (IPF) have been established to better understand its natural history, though their size and duration of follow-up are limited. Here, we describe the large European MultiPartner IPF Registry (EMPIRE) and validate predictors of long-term survival in IPF. METHODS: The multinational prospective EMPIRE registry enrolled IPF patients from 48 sites in 10 Central and Eastern European countries since 2014. Survival from IPF diagnosis until death was estimated, accounting for left-truncation. The Cox proportional hazards regression model was used to estimate adjusted hazard ratios (HR) of death for prognostic factors, using restricted cubic splines to fit continuous factors. RESULTS: The cohort included 1620 patients (mean age at diagnosis 67.6 years, 71% male, 63% smoking history), including 75% enrolled within 6 months of diagnosis. Median survival was 4.5 years, with 45% surviving 5 years post-diagnosis. Compared with GAP stage I, mortality was higher with GAP stages II (HR 2.9; 95% CI: 2.3-3.7) and III (HR 4.0; 95% CI: 2.8-5.7) while, with redefined cut-offs, the corresponding HRs were 2.7 (95% CI: 1.8-4.0) and 5.8 (95% CI: 4.0-8.3) respectively. Mortality was higher with concurrent pulmonary hypertension (HR 2.0; 95% CI: 1.5-2.9) and lung cancer (HR 2.6; 95% CI: 1.3-4.9). CONCLUSIONS: EMPIRE, one of the largest long-term registries of patients with IPF, provides a more accurate confirmation of prognostic factors and co-morbidities on longer term five-year mortality. It also suggests that some fine-tuning of the indices for mortality may provide a more accurate long-term prognostic profile for these patients.
650    _2
$a senioři $7 D000368
650    _2
$a komorbidita $7 D015897
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a idiopatická plicní fibróza $x epidemiologie $7 D054990
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    12
$a registrace $7 D012042
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a míra přežití $x trendy $7 D015996
650    _2
$a časové faktory $7 D013997
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Šterclová, Martina $u Department of Respiratory Medicine of the First Faculty of Medicine Charles University, Thomayer Hospital, Vídeňská 800, 140 59, Prague 4, Czech Republic.
700    1_
$a Mogulkoc, Nesrin $u Department of Chest Diseases, Faculty of Medicine, Ege University, Izmir, Turkey.
700    1_
$a Lewandowska, Katarzyna $u 1st Department of Pulmonary Diseases, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
700    1_
$a Müller, Veronika $u Department of Pulmonology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Hájková, Marta $u Clinic of Pneumology and Phthisiology, University Hospital Bratislava, Bratislava, Slovakia.
700    1_
$a Kramer, Mordechai R $u Institute of Pulmonary Medicine, Rabin Medical Center, Petah Tikva, Israel.
700    1_
$a Jovanović, Dragana $u University Hospital of Pulmonology, Clinical Center of Serbia, Belgrade, Serbia.
700    1_
$a Tekavec-Trkanjec, Jasna $u Department of Pulmonology, Clinical Hospital Dubrava, Zagreb, Croatia.
700    1_
$a Studnicka, Michael $u Clinical Research Center Salzburg, Salzburg, Austria.
700    1_
$a Stoeva, Natalia $u Department of Pulmonology, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria.
700    1_
$a Hejduk, Karel $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Dušek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Suissa, Samy $u Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
700    1_
$a Vašáková, Martina $u Department of Respiratory Medicine of the First Faculty of Medicine Charles University, Thomayer Hospital, Vídeňská 800, 140 59, Prague 4, Czech Republic. martina.vasakova@ftn.cz.
710    2_
$a EMPIRE registry
773    0_
$w MED00006600 $t Respiratory research $x 1465-993X $g Roč. 21, č. 1 (2020), s. 11
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31915023 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154435 $b ABA008
999    __
$a ok $b bmc $g 1608947 $s 1119792
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 1 $d 11 $e 20200108 $i 1465-993X $m Respiratory research $n Respir Res $x MED00006600
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace